LIC MF Healthcare Fund Direct Growth
EquitySector - HealthcareVery High Risk
Direct
NAV (22-Oct-24)
Returns (Since Inception)
Fund Overview
Fund Size
₹75 Cr
Expense Ratio
1.21%
ISIN
INF397L01LK4
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
28 Feb 2019
About this fund
As of 22-Oct-24, it has a Net Asset Value (NAV) of ₹31.65, Assets Under Management (AUM) of 75.05 Crores, and an expense ratio of 1.21%.
- LIC MF Healthcare Fund Direct Growth has given a CAGR return of 22.63% since inception.
- The fund's asset allocation comprises around 96.92% in equities, 0.00% in debts, and 3.08% in cash & cash equivalents.
- You can start investing in LIC MF Healthcare Fund Direct Growth with a SIP of ₹500 or a Lumpsum investment of ₹5000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+57.00%
+53.19% (Cat Avg.)
3 Years
+17.01%
+19.61% (Cat Avg.)
5 Years
+25.47%
+28.48% (Cat Avg.)
Since Inception
+22.63%
— (Cat Avg.)
Portfolio Summaryas of 30th September 2024
| Equity | ₹72.74 Cr | 96.92% |
| Others | ₹2.31 Cr | 3.08% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹8.55 Cr | 11.40% |
| Piramal Pharma Ltd | Equity | ₹5.82 Cr | 7.76% |
| Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹4.55 Cr | 6.06% |
| Torrent Pharmaceuticals Ltd | Equity | ₹4.21 Cr | 5.61% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹3.89 Cr | 5.19% |
| Cipla Ltd | Equity | ₹3.8 Cr | 5.06% |
| Mankind Pharma Ltd | Equity | ₹3.58 Cr | 4.77% |
| Treps | Cash - Repurchase Agreement | ₹3.47 Cr | 4.63% |
| Ipca Laboratories Ltd | Equity | ₹3.21 Cr | 4.28% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹3.1 Cr | 4.13% |
| Divi's Laboratories Ltd | Equity | ₹3.02 Cr | 4.02% |
| Abbott India Ltd | Equity | ₹2.99 Cr | 3.99% |
| Alkem Laboratories Ltd | Equity | ₹2.92 Cr | 3.89% |
| Zydus Lifesciences Ltd | Equity | ₹2.78 Cr | 3.71% |
| Suven Pharmaceuticals Ltd | Equity | ₹2.66 Cr | 3.55% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹2.58 Cr | 3.44% |
| Global Health Ltd | Equity | ₹2.41 Cr | 3.21% |
| Navin Fluorine International Ltd | Equity | ₹2.18 Cr | 2.91% |
| Laurus Labs Ltd | Equity | ₹2.11 Cr | 2.81% |
| Dr Reddy's Laboratories Ltd | Equity | ₹2 Cr | 2.67% |
| Metropolis Healthcare Ltd | Equity | ₹1.71 Cr | 2.28% |
| Neuland Laboratories Limited | Equity | ₹1.66 Cr | 2.21% |
| Syngene International Ltd | Equity | ₹1.58 Cr | 2.11% |
| Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹1.39 Cr | 1.85% |
| Net Receivables / (Payables) | Cash | ₹-1.16 Cr | 1.55% |
Allocation By Market Cap (Equity)
Large Cap Stocks
40.68%
Mid Cap Stocks
22.67%
Small Cap Stocks
31.36%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹68.9 Cr | 91.80% |
| Basic Materials | ₹2.18 Cr | 2.91% |
Risk & Performance Ratios
Standard Deviation
This fund
15.63%
Cat. avg.
15.87%
Lower the better
Sharpe Ratio
This fund
0.66
Cat. avg.
0.85
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.55
Higher the better
Fund Managers
Karan Doshi
Since July 2023
Additional Scheme Detailsas of 30th September 2024
ISIN INF397L01LK4 | Expense Ratio 1.21% | Exit Load 1.00% | Fund Size ₹75 Cr | Age 5 years 7 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹21.04 Cr | 54.2% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹888.27 Cr | 52.5% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹888.27 Cr | 50.5% |
| Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹39.61 Cr | 52.4% |
| ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹201.94 Cr | 53.3% |
| ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹201.94 Cr | 50.4% |
| Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2793.61 Cr | 53.2% |
| Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2793.61 Cr | 50.9% |
| Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹851.53 Cr | 51.7% |
| Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹19.51 Cr | 51.3% |
About the AMC
LIC Mutual Fund
Total AUM
₹1,733 Cr
Address
4th Floor, Industrial Assurance Building, Mumbai, 400 020
Other Funds by LIC Mutual Fund
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
|---|---|---|---|---|
| LIC MF Gold ETF FOF Direct Growth High Risk | 0.3% | 1.0% | ₹63.79 Cr | 28.0% |
| LIC MF Equity Savings Fund Direct Growth Moderately High risk | 1.0% | 1.0% | ₹21.68 Cr | 13.7% |
| LIC MF Nifty Next 50 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹101.48 Cr | 59.8% |
| LIC MF Focused 30 Equity Direct Growth Very High Risk | 1.6% | 1.0% | ₹154.22 Cr | 27.2% |
| LIC MF Long Term Value Fund Direct Growth Very High Risk | 1.6% | 1.0% | ₹132.22 Cr | 37.3% |
| LIC MF Healthcare Fund Direct Growth Very High Risk | 1.2% | 1.0% | ₹75.05 Cr | 57.0% |
| LIC MF Small Cap Fund Direct Growth Very High Risk | 1.5% | 1.0% | ₹370.18 Cr | 44.1% |
| LIC MF Midcap Fund Direct Growth Very High Risk | 1.6% | 1.0% | ₹334.33 Cr | 45.2% |
| LIC MF Dividend Yield Fund Direct Growth Very High Risk | 1.4% | 1.0% | ₹436.11 Cr | 53.1% |
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of LIC MF Healthcare Fund Direct Growth?
What are the returns of LIC MF Healthcare Fund Direct Growth?
What is the portfolio composition of LIC MF Healthcare Fund Direct Growth?
Who manages the LIC MF Healthcare Fund Direct Growth?
- Karan Doshi
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.